including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; our performance on and ability to comply with environmental, social and governance measures and requiremen...
诺华(Novartis)公司今天宣布,已收购了位于圣地亚哥的生物技术公司DTx Pharma,该公司专注于利用其专有的FALCON平台开发用于神经科学适应症的siRNA疗法。 DTx的主打项目DTx-1252靶向1A型腓骨肌萎缩症(CMT1A)的根源——PMP22蛋白的过度表达。PMP22是一种导致保护外周神经的髓鞘功能异常的蛋白。DTx-1252通过靶向编码PMP22的m...
We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential. In addition to two ...